2. Avivia History
• In 2005 Avivia started as a one-man company focussing on
providing consultancy services in pharmaceutical product
development
• In 2007 the company was restructured into a limited liability
company and the first personnel was hired
• In 2010 the decision was taken to scale down the consultancy
business and start investing in our own ideas and on setting up
joint ventures with other SME-companies
3. The opportunity to take the next step
• In 2013, Synthon announced that it would close down its small
molecule development activitities in Nijmegen, The Netherlands
• Several people saw this as an opportunity to make the change from
being an employee to becoming an entrepeneur
• In 2014, we started working together and through SMB we hired a
business consultant, Peter van de Laarse, to advice us on how best
to setup a combined business
4. Getting the basics right for Avivia 2.0
• Avivia 2.0 is a merger between 3 new one-man companies with an
inventory of equipment and an established company with a network,
running business and development projects
• Main issues that needed to be adressed:
- what assets does each individual company bring to the table
- what is the value of those assets within the new company
- how does that translate into the total value of the company and the
distribution of shares
- what is the optimal legal and fiscal setup for the new company
- who will lead the new company
- financial forecast and business plan (with a 7-year horizon)
- we have setup the control systems for our business, like the financial, project
and contract administration and time allocation
• Avivia 2.0 was legally formed on the 14th of July, 2015
5. Avivia Team
Slide
5
Within Avivia we have the capabilities and the
expertise to develop any pharmaceutical drug
product from scratch to cGMP
Menno Wiltink
Synthon
Analytical development
Hans Platteeuw
Synthon, Dafra, Avivia
Managing Director
Dennie van den Heuvel
Intervet, Synthon
Pharmaceutical Development
Hans van der Steen
CP Kelco, Synthon
Analytical Research
Thomas Verbeek
AUV veterinary
services
Controller
Marleen De Vriese
Dafra, Avivia
Project Manager
6. Avivia Professional Panel
Slide
6
In our operations we have close ties with a number
of professionals that work with us on a daily
basis in various aspects of our business.
Wout Wouters
Solvay, TNO, Pantarhei
In vitro testing and in
vivo animal studies
Han van ‘t Klooster
Pharmacytics, Chamaeleo
Business development
Laurens Theunis
Galapagos, Formac, Chamaeleo
Investment manager
Frank Vanderdonck
Pfizer, UCB, Ipsen,
Chamaeleo
Business Intelligence/Medical
Liaison Peter van de Laarse
PWC, Belastingdienst
Business Consultant
Gelein Platteeuw
Intervet/MSD
Facilities/Procurement
7. Avivia business
• Avivia has developed a number of opportunities for repurposing
of existing drugs in various clinical fields, e.g. Gastrointestinal
Inflammation, Womens’ Health, Oncology and Tropical Diseases
• We currently have 2 products in a screening stage, 3 in feasilibity
and 4 in proof of concept testing (phase II clinical testing in
patients/volunteers)
• We are also open for other companies to support them in their
product developments, either as a pure fee for service (contract
research) or in co-development deals
Slide
7
8. Avivia within 5 years
• Within 5 years aim to become a flexible, dedicated, creative
pharmaceutical product innovation company with a focus on drug
repurposing programs
• We expect to employ 20-25 people and have an annual turnover of
at least 10 million Euro
9. For more information, please contact:
9
Hans Platteeuw
Van Leeuwenhoekweg 12
5482 TK Schijndel
The Netherlands
Mobile: + 31 6 286 75 973
E-mail: hansplatteeuw@avivia.nl
Skype: hans.platteeuw
